Salix Pharmaceuticals, a division of Bausch Health US, LLC
$4.4M 161,040 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Octapharma USA, Inc.
Octapharma USA, Inc. reported $4,421,793.52 across General Payments, Research, and Ownership to 5,207 physicians and teaching hospitals across 5,449 transactions.
- $4.4M Top quartile payer
- All-tracks total
- 5,449 Top quartile volume
- Transactions
- 5,207 Top quartile reach
- Recipients
- +$620.7K
- General Payments vs PY2023
Octapharma USA, Inc. reported $4,421,793.52 across all CMS Open Payments tracks (General + Research + Ownership) to 5,207 physicians and teaching hospitals in Program Year 2024 - ranking #292 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,023,395.55, averaging $849.20 per recipient.
How Octapharma USA, Inc.'s $4.4M all-tracks total breaks down
Octapharma USA, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
57/100
Total payments
D
51/100
Transaction volume
D
50/100
Physician reach
D
50/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer octapharma-usa-inc Octapharma USA, Inc.
$4.4M · #292/1,925 · 0.0% industry · PY2024
- TOT $4.4M
- RANK #292
- SHARE 0.0%
- TXN 5,449
- RCP 5,207
- CAT 6
- GEN $1.0M
- ΔGEN +$620.7K
- TOP1 13.9%
- PY 2024
Volume peers
Nearest volume peer: Salix Pharmaceuticals, a division of Bausch Health US, LLC ($4.4M)
Octapharma USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Octapharma USA, Inc.'s CMS-reported General Payments increased by $620.7K (+154.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: OCTAPHARMA USA, INC.PY2023: OCTAPHARMA USA, INC.PY2024: Octapharma USA, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $402,646.73
- PY2024
- $1,023,395.55
What the Data Shows for Octapharma USA, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Octapharma USA, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
7 transactions worth $359.5K make "Compensation for Services Other Than Consulting" the top general-payment category in the 6-category breakdown below, 35.1% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Octapharma USA, Inc. made 6 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $359.5K, 35.1% of General Payments.
Octapharma USA, Inc. reports 6 general-payment categories - the top three are Compensation for Services Other Than Consulting (35.1%), Travel and Lodging (25.2%), and Honoraria (18.0%). The remaining 3 categories make up 21.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Octapharma USA, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $359.5K | 7 | 35.1% |
| Travel and Lodging | $257.4K | 187 | 25.2% |
| Honoraria | $184.4K | 65 | 18.0% |
| Food and Beverage | $132.9K | 4,917 | 13.0% |
| Grant | $87.5K | 4 | 8.5% |
| Consulting Fee | $1.7K | 27 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $409,273.08 (40.0%) of $1,023,395.55 in this company's General Payments records across 3,055 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Octapharma USA, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Isaac Melamed
$142,338.49 across 15 reported transactions
- 2
Lawrence Steinman
$114,105.00 across 1 reported transactions
- 3
Mazen Dimachkie
$57,500.00 across 3 reported transactions
- 4
Robert Sidonio
$50,329.59 across 15 reported transactions
- 5
Jennifer Frankovich
$45,000.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Octapharma USA, Inc. ranks #292 of 1,925 by total payments (top 15% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,302 of 1,838 by HHI (bottom 29% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Arjo Inc. : $151.8K total payments, HHI 489
- Banner Life Sciences, LLC : $82.4K total payments, HHI 487
- FUJIFILM Sonosite, Inc. : $257.0K total payments, HHI 486
- restor3d, inc. : $1.6M total payments, HHI 486
- Micro-tech Endoscopy USA, Inc. : $159.3K total payments, HHI 483
- International Life Sciences : $883.8K total payments, HHI 481
- Octapharma USA, Inc. (this company) : $1.0M total payments, HHI 480
- Alliance Medical : $6.2K total payments, HHI 480
- Kyocera Medical Technologies, Inc. : $689.6K total payments, HHI 480
- GC America Inc. : $524.2K total payments, HHI 479
- Align Technology, Inc. : $16.8M total payments, HHI 478
- Canon Medical Systems USA, Inc. : $437.4K total payments, HHI 477
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Octapharma USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Octapharma USA, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Octapharma USA, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Exact Sciences Corporation
$4.4M 107,493 recipients
Compare payment profiles
Novocure Inc.
$4.5M 3,615 recipients
Compare payment profiles
bluebird bio, Inc.
$4.5M 229 recipients
Compare payment profiles
Bolton Medical Inc
$4.4M 4,442 recipients
Compare payment profiles
Kerecis Limited
$4.3M 26,463 recipients
Compare payment profiles
Put this to use
Octapharma USA, Inc. ranks #292 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Octapharma USA, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Octapharma USA, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.